Ventas (VTR) to Release Earnings on Thursday

Ventas (NYSE:VTR) will likely be posting its Q4 2025 results after the market closes on Thursday, February 5th. Analysts expect Ventas to post earnings of $0.89 per share and revenue of $1.5325 billion for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, February 6, 2026 at 10:00 AM ET.

Ventas (NYSE:VTR) last issued its quarterly earnings data on Wednesday, October 29th. The real estate investment trust reported $0.88 EPS for the quarter, topping the consensus estimate of $0.87 by $0.01. The business had revenue of $1.49 billion during the quarter, compared to analyst estimates of $1.44 billion. Ventas had a net margin of 4.28% and a return on equity of 2.05%. The company’s revenue for the quarter was up 20.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.80 EPS. On average, analysts expect Ventas to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Ventas Trading Down 0.1%

Shares of VTR opened at $75.88 on Thursday. Ventas has a 1-year low of $58.72 and a 1-year high of $81.89. The company has a current ratio of 0.32, a quick ratio of 0.32 and a debt-to-equity ratio of 1.01. The firm’s 50-day moving average price is $78.30 and its 200-day moving average price is $72.62. The firm has a market capitalization of $35.64 billion, a price-to-earnings ratio of 145.92, a PEG ratio of 1.88 and a beta of 0.78.

Ventas Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 15th. Shareholders of record on Wednesday, December 31st were given a dividend of $0.48 per share. This represents a $1.92 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend was Wednesday, December 31st. Ventas’s payout ratio is presently 369.23%.

Analyst Ratings Changes

Several brokerages have recently issued reports on VTR. Jefferies Financial Group reissued a “buy” rating and issued a $93.00 target price on shares of Ventas in a research report on Monday, December 15th. Wells Fargo & Company increased their price objective on Ventas from $80.00 to $88.00 and gave the stock an “overweight” rating in a report on Tuesday, November 25th. Scotiabank boosted their target price on shares of Ventas from $74.00 to $80.00 and gave the company a “sector perform” rating in a report on Thursday, November 13th. Weiss Ratings raised shares of Ventas from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, December 29th. Finally, The Goldman Sachs Group started coverage on shares of Ventas in a research report on Friday, January 9th. They set a “buy” rating and a $94.00 price target for the company. Fourteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $81.63.

Insider Buying and Selling

In other news, CEO Peter J. Bulgarelli sold 3,924 shares of the business’s stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $75.00, for a total value of $294,300.00. Following the completion of the transaction, the chief executive officer owned 112,564 shares in the company, valued at $8,442,300. The trade was a 3.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Debra A. Cafaro sold 41,294 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $79.01, for a total value of $3,262,638.94. Following the sale, the chief executive officer directly owned 1,145,695 shares in the company, valued at $90,521,361.95. This trade represents a 3.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 176,747 shares of company stock worth $13,579,533 in the last three months. Insiders own 1.00% of the company’s stock.

Hedge Funds Weigh In On Ventas

A number of hedge funds have recently bought and sold shares of the business. CIBC Private Wealth Group LLC grew its stake in shares of Ventas by 62.8% in the third quarter. CIBC Private Wealth Group LLC now owns 7,599 shares of the real estate investment trust’s stock worth $532,000 after acquiring an additional 2,932 shares during the period. Captrust Financial Advisors boosted its holdings in Ventas by 14.2% in the third quarter. Captrust Financial Advisors now owns 38,415 shares of the real estate investment trust’s stock worth $2,689,000 after purchasing an additional 4,764 shares during the last quarter. Coldstream Capital Management Inc. grew its position in Ventas by 4.5% in the 3rd quarter. Coldstream Capital Management Inc. now owns 6,910 shares of the real estate investment trust’s stock worth $484,000 after purchasing an additional 299 shares during the period. Danske Bank A S purchased a new stake in Ventas during the 3rd quarter valued at $14,929,000. Finally, Morningstar Investment Management LLC purchased a new stake in Ventas during the 3rd quarter valued at $233,000. Hedge funds and other institutional investors own 94.18% of the company’s stock.

Ventas Company Profile

Ventas, Inc (NYSE: VTR) is a real estate investment trust (REIT) that specializes in healthcare-related real estate. The company acquires, owns and manages a diversified portfolio of properties serving the healthcare continuum, including senior housing communities, skilled nursing facilities, medical office buildings, life science and research centers, and other properties leased to healthcare providers and operators. Ventas generates revenue through long-term leases, property management and selective development activities focused on meeting the real estate needs of the healthcare sector.

Ventas’ business model combines property ownership with active asset management and capital markets activity.